# Mazdutide

Canonical source: https://retacompare.com/encyclopedia/mazdutide

Dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly's OXM3 program.

Reference facts

Also known asIBI362, OXM3CategoryGLP-1 & MetabolicMechanism of actionDual GLP-1 / glucagon receptor agonist licensed from Eli Lilly's OXM3 program.TargetsGLP-1R, GCGRIndications under research or approvedObesity, Type 2 Diabetes, MASHRegulatory status (reference entry)Approved in China (2025); Phase 3 in other regionsHalf-life~140 hours (~6 days)SequenceHSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIASequence notesOxyntomodulin analog with dual GLP-1 / glucagon activity; C18 fatty acid linker.Molecular weight (Da)4400Originator / sponsorInnovent Biologics (China license from Eli Lilly)First reported2020
    Primary References

Mazdutide GLORY-1 Phase 3 obesity 2024


    Explore research articles about Mazdutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Mazdutide GLORY-1 Phase 3 obesity 2024: https://pubmed.ncbi.nlm.nih.gov/39419071/